CADTH | Evidence Driven
CADTH | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
N/A panitumumab Left-sided metastatic colorectal cancer (mCRC) Reimburse with clinical criteria and/or conditions Active
Lynparza olaparib Metastatic castration-resistant prostate cancer (mCRPC) Reimburse with clinical criteria and/or conditions Active
Amvuttra vutrisiran Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) Reimburse with clinical criteria and/or conditions Active
Leqvio inclisiran Primary hypercholesterolemia Active
Bylvay odevixibat Progressive familial intrahepatic cholestasis (PFIC) Reimburse with clinical criteria and/or conditions Active
Opdualag nivolumab and relatlimab unresectable or metastatic melanoma Reimburse with clinical criteria and/or conditions Active
Trecondyv treosulfan Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) Reimburse with clinical criteria and/or conditions Active
Trodelvy sacituzumab govitecan HR+, HER2− advanced or metastatic breast cancer Reimburse with clinical criteria and/or conditions Active
Rezurock belumosudil Graft-versus-host disease Reimburse with clinical criteria and/or conditions Active
N/A eltrombopag Severe Aplastic Anemia (SAA) Reimburse with clinical criteria and/or conditions Active
Last Updated : April 25, 2024